$IKT (Inhibikase Therapeutics) Long:
- On 06/16/2021 priced a public offering of 15 million common shares at $3 per share
- On 07/26/2021 received clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.
- Unusual volume recently
- Bullish divergence with RSI
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
If you understand the...